Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of pharmacologic FSH inhibition on gene expression

ABSTRACT: see Super Series Summary

ORGANISM(S): Drosophila melanogaster

PROVIDER: GSE36180 | GEO | 2013/02/06

SECONDARY ACCESSION(S): PRJNA155781

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effects of pharmacologic FSH inhibition on gene expression

Project description:see Super Series Summary We treated Drosophila S2-DRSC cells for 1, 2, 4 and 20 h with 10 µM JQ1 and compared their gene expression to DMSO-treated control cells (1 and 20 h).

2013-02-06 | E-GEOD-36180 | biostudies-arrayexpress

Effects of FSH knockdown on gene expression

Project description:see Super Series Summary

2013-02-06 | GSE43180 | GEO

Effects of FSH knockdown on gene expression

Project description:see Super Series Summary Gene expression profiles of Drosophila S2-DRSC FSH knockdown cells were generated by Illumna RNA sequencing and compared to profiles derived from control cells (eGFP knockdown).

2013-02-06 | E-GEOD-43180 | biostudies-arrayexpress

Generation of chromatin maps for ASH1 and FSH applying ChIP-seq

Project description:see Super Series Summary

2013-02-06 | GSE36404 | GEO

Generation of chromatin maps for ASH1 and FSH applying ChIP-seq

Project description:see Super Series Summary Cross-linked chromatin derived from Drosophila S2-DRSC cells was immunoprecipitated using antibodies targeting ASH1 and FSH. Precipitated chromatin was sequenced applying Illumina sequencing.

2013-02-06 | E-GEOD-36404 | biostudies-arrayexpress

Pharmacologic inhibition of STAT5 in AML

Project description:The transcription factors STAT5A and STAT5B are essential downstream mediators of many tyrosine kinases, particularly in hematopoietic cancers. As such, STAT5 is activated by FLT3-ITD, which is a constitutively active tyrosine kinase driving the pathogenesis of acute myeloid leukemia (AML). Since STAT5 is a critical mediator of diverse malignant properties of AML cells, direct targeting of STAT5 function is of significant clinical value. Here, we describe the novel small molecular weight inhibitor AC-4-130 that directly binds to the phosphotyrosine (pY)-binding pocket of the STAT5 SH2 domain, thereby disrupting STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent induction of gene transcription. AC-4-130 substantially impaired the proliferation and clonogenic growth of human AML cell lines and primary FLT3-ITD+ AML patient cells in vitro and in vivo. Importantly, AC-4-130 synergistically increased the cytotoxicity of the JAK1/2 inhibitor Ruxolitinib and the p300/pCAF inhibitor Garcinol. In summary, we report the development and preclinical evaluation of a novel, potent STAT5 SH2 domain inhibitor that can efficiently block pathological levels of STAT5 activity in AML. The synergistic effects of AC-4-130 tyrosine kinase inhibitors as well as emerging treatment strategies provide new opportunities for combinatorial treatment of leukemia and potentially other cancers.

2018-09-03 | GSE103510 | GEO

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-07-16 | E-GEOD-59497 | biostudies-arrayexpress

Gene expression analysis of bovine oocytes with high developmental competence obtained from FSH-stimulated animals

Project description:The objective of the study was to analyze the impact of various lenght FSH withdrawal period (coasting) after the last FSH injection on transcriptome changes in in vivo bovine oocytes at the GV stage. Oocytes were collected from super-stimulated animals after 20, 44, 68 and 92 hours of coasting.

2013-06-21 | GSE38345 | GEO

Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats.

Project description:Anemia of chronic inflammation (ACI) is the most frequent anemia in hospitalized patients and is associated with significant morbidity. A major underlying mechanism of ACI is the retention of iron within cells of the reticuloendothelial system (RES), thus making the metal unavailable for efficient erythropoiesis. This reticuloendothelial iron sequestration is primarily mediated by excess levels of the iron regulatory peptide hepcidin down-regulating the functional expression of the only known cellular iron export protein ferroportin resulting in blockade of iron egress from these cells. Using a well-established rat model of ACI, we herein provide novel evidence for effective treatment of ACI by blocking endogenous hepcidin production using the small molecule dorsomorphin derivative LDN-193189 or the protein soluble hemojuvelin-Fc (HJV.Fc) to inhibit bone morphogenetic protein-Smad mediated signaling required for effective hepcidin transcription. Pharmacologic inhibition of hepcidin expression results in mobilization of iron from the RES, stimulation of erythropoiesis and correction of anemia. Thus, hepcidin lowering agents are a promising new class of pharmacologic drugs to effectively combat ACI.

| S-EPMC3208302 | biostudies-literature

Gallus gallus

Project description:Chicken QTLdb reports QTLs for 164 traits collected from 70 publications (see database summary at http://www.animalgenome.org/cgi-bin/QTLdb/GG/summary).

| PRJNA42171 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data